DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 124-131

  Müller, Cristina ^a   Struthers, Harriet ^b   Winiger, Christian ^b   Zhernosekov, Konstantin ^a,c   Schibli, Roger ^a,b  

^a ETH Zurich   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

177Lu cm09; Albumin binder; Folate receptor; Radionuclide therapy; SPECT

Indexed keywords

FOLIC ACID; LUTETIUM TETRAXETAN FOLATE CONJUGATE LU 177; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RADIATION DOSE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; TISSUE DISTRIBUTION; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRAFILTRATION;

ALBUMINS; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FOLIC ACID; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KB CELLS; LUTETIUM; MICE; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOISOTOPES;

EID: 84872042051     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107235     Document Type: Article

References (40)

1. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 1991;51:6125-6132.
2. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
3. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;142:557-567.
4. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284-293.
5. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41:120-129.
6. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13:256-262.
7. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008;27:655-664.
8. Müller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptorpositive cancer. J Nucl Med. 2011;52:1-4.
9. Müller C. Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation. Curr Pharm Des. 2012;18:1058-1083.
10. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94:2135-2146.
11. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007;26:141-152.
12. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127-1141.
13. Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem. 2005;16:803-811.
14. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol. 2006;58:229-236.
15. Reddy JA, Westrick E, Santhapuram HK, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res. 2007;67:6376-6382.
16. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007;67:4434-4442.
17. Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 2009;49:1467-1476.
18. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38:358-366.
19. Druce MR, Lewington V, Grossman AB. Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Neuroendocrinology. 2010;91:1-15.
20. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011;17:6406-6416.
21. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev. 2004;56:1143-1160.
22. Holm J, Hansen SI, Hoiermadsen M, Bostad L. A high-affinity folate binding-protein in proximal tubule cells of human kidney. Kidney Int. 1992;41:50-55.
23. Birn H, Spiegelstein O, Christensen EI, Finnell RH. Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol. 2005;16:608-615.
24. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol. 2004;287:C517-C526.
25. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem. 2002;277:35035-35043.
26. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261.
27. Dumelin CE, Trussel S, Buller F, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl. 2008;47:3196-3201.
28. Trü ssel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem. 2009;20:2286-2292.
29. 67Ga-DOTA-Bz-folate: investigations of methods to improve the tissue distribution of radiofolates. Nucl Med Biol. 2011;38:715-723.
30. Ladino CA, Chari RVJ, Bourret LA, Kedersha NL, Goldmacher VS. Folatemaytansinoids: target-selective drugs of low molecular weight. Int J Cancer. 1997;73:859-864.
31. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 1996;37:1003-1008.
32. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy. Eur J Nucl Med Mol Imaging. 2009;36:938-946.
33. 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging. 2006;33:1007-1016.
34. 99mTc-technetium(I)- and Re-rhenium(I)-folate derivatives for potential use in nuclear medicine. J Organomet Chem. 2004;689:4712-4721.
35. 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer. J Nucl Med. 2008;49:623-629.
36. Müller C, Brühlmeier M, Schubiger AP, Schibli R. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. J Nucl Med. 2006;47:2057-2064.
37. 99mTc-EC20 in xenografted and syngeneic tumor-bearing mice. Mol Pharm. 2010;7:597-604.
38. Fani M, Wang X, Nicolas G, et al. Development of new folate-based PET radiotracers: preclinical evaluation of Ga-DOTA-folate conjugates. Eur J Nucl Med Mol Imaging. 2011;38:108-119.
39. 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004;45:857-866.
40. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.